Clinical Scorecard: Economic Evaluation of Anticoagulant Therapy for Subclinical Atrial Fibrillation Detected by Devices
At a Glance
Category
Detail
Condition
Subclinical Atrial Fibrillation
Key Mechanisms
Anticoagulation for stroke prevention and risk of major bleeding.
Target Population
Patients with device-detected subclinical atrial fibrillation, particularly those aged around 77 years.
Care Setting
Health system perspective, focusing on direct medical costs.
Key Highlights
Anticoagulation modestly reduces stroke risk but increases major bleeding risk.
Cost-effectiveness of DOAC therapy remains uncertain despite marginal clinical benefits.
Modeling study utilized a Markov model with a 10-year simulation for 10,000 individuals.
Guideline-Based Recommendations
Diagnosis
Device-detected atrial fibrillation should be evaluated for potential anticoagulation.
Management
Consider anticoagulation based on existing clinical practice guidelines for atrial fibrillation.
Monitoring & Follow-up
Monitor for major bleeding events and adjust therapy as necessary.
Risks
Increased risk of major bleeding associated with DOAC therapy.
Patient & Prescribing Data
77-year-old patients without prior clinical AF.
Anticoagulation not significantly affecting mortality; focus on stroke and bleeding outcomes.
Clinical Best Practices
Utilize a health system perspective for cost-effectiveness evaluations.
Incorporate health-related quality-of-life decrements in treatment assessments.
Related Resources & Content
JAMA Network Open, 2023 -- Anticoagulation in Device-Detected Atrial Fibrillation—Uncertainty and Heterogeneity in Value
Clinical Research in Cardiology, 2022 -- Managing Patients with Subclinical Atrial Fibrillation and Atrial High-Rate Episodes: Evidence and Clinical Significance
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | New England Journal of Medicine
Clinical Research in Cardiology (Springer) — Comparison of therapeutic strategies in patients presenting with left atrial thrombus despite oral anticoagulation
Clinical Research in Cardiology — Evaluation of Treatment Approaches for Atrial Fibrillation Patients with Left Atrial Appendage Thrombus Despite Optimal NOAC Management
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | New England Journal of Medicine
Practical Recommendations for Anticoagulation in Patients With Atrial Fibrillation - Johner - 2026 - European Journal of Clinical Investigation - Wiley Online Library
